Filter

Refine by Content Type

Refine by ASN Kidney News

  • Features (1)

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 1 - 1 of 1 items for :

  • Author or Editor: Andrew M. South x
  • Refine by Content Type: All x
Clear All Modify Search
Cover Kidney News
An Update on Novel Soluble ACE2 Therapeutics to Treat SARS-CoV-2: Insights from a Preclinical Study
Andrew M. South and Matthew A. Sparks

Novel therapeutics remain urgently needed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19), including associated acute kidney injury. Angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 spike protein-binding site, is expressed in numerous tissues, including the lungs and kidneys. Soluble ACE2 is a potential therapeutic with dual roles: 1) binding SARS-CoV-2 to attenuate infection and replication and 2) shifting the renin-angiotensin system away from the pro-inflammatory angiotensin II and bradykinin pathways. There is precedent for using recombinant soluble ACE2 clinically. A pilot randomized clinical trial in 44 patients with acute respiratory distress syndrome (pre-COVID-19